Following his presentation at ACR 2020, we spoke with Richard Furie (Northwell Health Zucker School of Medicine at Hofstra/Northwell, NY, USA) about the novel IL-2 conjugate, NKTR-358 in patients with systemic lupus erythematosus (Clinical Trial Identifier: NCT03556007). The abstract ‘Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358.’ (ABSTRACT NUMBER: 1824) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you give us a brief overview of therapeutic advances in systemic lupus erythematosus (SLE) in recent years? (0:26)
- What unmet needs remain in the treatment of SLE? (1:54)
- What is NKTR-358 and what is the rationale for its use in SLE? (2:32)
- Could you tell us about the Phase 1b study of NKTR-358 and its findings? (5:25)
- What will be the next step in the clinical development of NKTR-358? (9:36)
Disclosure: Dr. Furie has received personal research consulting fees as well as research support from Nektar and Eli Lilly.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!